Interactions between immunoglobulin G molecules

Immunology Letters

Volumn 132, Issue 1-2, 2010, Pages 1-5

  Nezlin, Roald ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

IgG aggregates; IgG dimers; IgG networks; IgG IgG interactions; Prevention of IgG aggregation; Therapeutic immune globulins

Indexed keywords

DIMER; HYDROXYAPATITE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN IDIOTYPE; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AUTOIMMUNE DISEASE; CHROMATOGRAPHY; DRUG MEGADOSE; DRUG STORAGE; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; IMMUNOGLOBULIN AGGREGATE; IMMUNOPRECIPITATION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SITE DIRECTED MUTAGENESIS; SPIN LABELING; VISCOSITY; X RAY CRYSTALLOGRAPHY; CHEMISTRY; METABOLISM;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; PROTEIN BINDING;

EID: 77955013611     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.06.006     Document Type: Review

References (44)

1. Nezlin R., Gheţie V. Interactions of immunoglobulins outside the antigen-combining site. Adv Immunol 2004, 82:155-215.
2. Nezlin R. Circulating non-immune IgG complexes in health and disease. Immunol Lett 2009, 122:141-144.
3. Gronsky P., Seiler F.R., Schwick H.G. Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990. Mol Immunol 1991, 28:1321-1332.
4. Tankerslay D.L., Preston M.S., Finlayson J.S., Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988, 25:41-48.
5. Roux K.H., Tankerslay D.L. A view of the human idiotypic repertoire. Electron microscopic and immunologic analysis of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990, 144:1387-1395.
6. Nezlin R. Internal movements in immunoglobulin molecules. Adv Immunol 1990, 40:1-40.
7. Hall C.G., Abraham G.N. Reversible self-association of a human myeloma protein. Thermodynamics and relevance to viscosity effects and solubility. Biochemistry 1984, 23:5123-5129.
8. Jiménez M., Rivas G., Minton A.P. Quantitative characterization of weak self-association in concentrated solutions of IgG via the measurement of sedimentation equilibrium and osmotic pressure. Biochemistry 2007, 46:8373-8378.
9. Liu J., Nguyen M.D.H., Andya J.D., Shire S.J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 2005, 94:1928-1940.
10. Harn N., Allan C., Oliver C., Middaugh C.R. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J Pharm Sci 2007, 96:532-546.
11. Dani B., Platz R., Tzannis S.T. Pharmaceutics, preformulation and drug delivery. High concentration formulation feasibility of human IgG for subcutaneous administration. J Pharm Sci 2007, 96:1504-1517.
12. Chirino A.J., Ary M.L., Marshall S.A. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004, 9:82-90.
13. Kanai S., Liu J., Pataroff T.W., Shire S.J. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 2008, 97:4219-4227.
14. Kamerzell T.J., Kanai S., Liu J., Shire S.J., Wang Y.J. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J Phys Chem B 2009, 113:6109-6118.
15. Kabat E.A. Experimental immunochemistry 1961, CC Thomas, Springfield, IL, USA.
16. Møller N.P.H. Fc-mediated immune precipitation I. A new role of the Fc-portion of IgG. Immunology 1979, 38:631-640.
17. Møller N.P.H., Christiansen G. Fc-mediated immune precipitation. III. Visualization by electron microscopy. Immunology 1983, 48:469-476.
18. Møller N.P.H., Pedersen T.S. Fc-mediated immune precipitation IV. Antigen dependency and specificity. Immunology 1983, 48:477-488.
19. Karush F. The affinity of antibody: range, variability, and the role of multivalence. Comprehensive immunology. Immunoglobulins 1978, vol. 5:85-116. New York, Plenum.
20. Rodwell J.D., Tang L.-H., Schumaker V.N. Antigen valence and Fc-localized secondary forces in antibody precipitation. Mol Immunol 1980, 17:1591-1597.
21. Easterbrook-Smith S.B., Vandenberg R.J., Alden J.R. The role of Fc:Fc interactions in insoluble immune complex formation and complement activation. Mol Immunol 1988, 25:1331-1337.
22. Nezlin R. The immunoglobulins. Structure and function 1998, Acad. Press, San Diego, USA.
23. Cathou R.E., Haber E. Structure of the antibody combining site. I. Hapten stabilization of antibody conformation. Biochemistry 1967, 6:513-518.
24. Cohen P.L., Cheek R.L., Hadler J.A., Yount W.J., Eisenberg R.A. The subclass distribution of human IgG rheumatoid factor. J Immunol 1987, 139:1466-1471.
25. Zack D.J., Stempniak M., Wong A.L., Weisbart R.H. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol 1995, 155:5057-5063.
26. Butler J.E., Ni L., Brown W.R., Joshi K.S., Chang J., Rosenberg B., et al. The immunochemistry of sandwich ELISAs-VI. Greater that 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denaturated by passive adsorption. Mol Immunol 1993, 30:1165-1175.
27. Rispens T., Heer P.O.D., Vermeulen E., Schuurman J., Kolfschoten M.N., Aalberse R.C. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol 2009, 182:4275-4281.
28. Abaturov L.V., Nezlin R.S., Vengerova T.I., Varshavski Y.M. Conformational studies of IgG and its subunits by the methods of hydrogen-deuterium exchange and infrared spectroscopy. Biochem Biophys Acta 1969, 194:386-396.
29. Rispens T., Himly M., Heer P.O.D., Bleker T.H.D., Aalberse R.C. Traces of pFc' in IVIG interact with human IgG Fc domains and counteract aggregation. Eur J Pharm Sci 2010.
30. Nezlin R., Sykulev Y.K. Structural studies of immunoglobulins spin-labeled at the carbohydrate moiety. Mol Immunol 1982, 19:357-366.
31. Kusumi A., Winkelhake J.L. Fc:Fc interactions revealed by spin-labeled IgG heterosaccharides in model immune complexes. Biochem Biophys Res Commun 1986, 137:237-243.
32. Kolenko P., Dohnálek J., Dušková J., Skálová T., Collard R., Hašek J. New insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2.1-Å resolution. Immunology 2008, 126:378-383.
33. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287:1279-1285.
34. Chennamsetty N., Helk B., Voynov V., Kayser V., Trout B.L. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 2009, 391:404-413.
35. Chennamsetty N., Voynov V., Kayser V., Helk B., Trout B.L. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 2009, 106:11937-11942.
36. Cummings L.J., Snyder M.A., Brisack K. Protein chromatography on hydroxyapatite columns. Methods Enzymol 2009, 463:387-404.
37. Schubert S., Freitag R. Investigation of the interaction mechanism of the recombinant human antibody MDJ8 and is fragments with chromatographic apatite phases. J Chromatogr 2009, 1216:3831-3840.
38. Gagnon P. Monoclonal antibody purification with hydroxyapatite. New Biotechnol 2009, 25:287-293.
39. Gagnon P. Improved antibody aggregate removal by hydroxyapatite chromatography in the presence of polyethylene glycol. J Immunol Methods 2009, 336:222-228.
40. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
41. Tankerslay D.L. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune disease. Immunol Rev 1994, 139:159-172.
42. Gronski P. IgG dimers in multidonor-derived immunoglobulins: aspects of generation and function. Curr Pharm Des 2006, 12:181-190.
43. Yoo E.M., Wims L.A., Chan L.A., Morrison S.L. Human IgG2 can form covalent dimers. J Immunol 2003, 170:3134-3138.
44. Bolli R., Woodtli K., Bärtschi M., Höfferer L., Lerch P. l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 2010, 38:150-157.